Associations - RUNX1 mutation

BIOMARKER:

RUNX1 mutation

Entrez ID:

861

Related biomarkers:

‹

›

RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: C2 – Inclusion Criteria EHA 2021 - 4 days venetoclax Sensitive : C2 EHA 2021 - 4d
RUNX1 mutation RUNX1 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	venetoclax + RO5503781 Sensitive: C3 – Early Trials venetoclax + RO5503781 Sensitive : C3
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine/daunorubicin liposomal formulation Resistant : C3
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	cytarabine Resistant: C3 – Early Trials cytarabine Resistant : C3
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	tagraxofusp Sensitive: D – Preclinical tagraxofusp Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES